AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31226238 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable implant (Latera)
Number of subjects: 137
Study 27821639 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mastoid electrical stimulator (PMES)
Number of subjects: 0
Study 27821639 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 27821639 — intervention group
Group type: EXPERIMENTAL
Intervention: PMES
Number of subjects: 0
Study 25029005 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg.kg of body mass
Number of subjects: 13
Study 25029005 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg.kg of body mass
Number of subjects: 13
Study 25029005 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg.kg of body mass)
Number of subjects: 13
Study 23494615 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-machine interface (BMI) training
Number of subjects: 32
Study 23494615 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham group)
Number of subjects: 32
Study 21510785 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed awareness of campaign advertising
Number of subjects: 5616
Study 19620845 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 16965211 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling (IPC)
Number of subjects: 19
Study 16965211 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 19
Study 15237655 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin (300 ml per day for 72 hours)
Number of subjects: 61
Study 15237655 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 500 ml (per day for 72 hours)
Number of subjects: 61
Study 15237655 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 1000 ml (per day for 72 hours)
Number of subjects: 61
Study 15237655 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1000 ml per day for 72 hours)
Number of subjects: 61
Study 11236257 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (40 patients with stabilized UA after pharmacological treatment)
Number of subjects: 54
Study 11236257 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (14 patients with significant cardiac events during hospitalization)
Number of subjects: 54
Study 11236257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died during hospitalization
Number of subjects: 54
Study 11236257 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 healthy subjects)
Number of subjects: 54
Study 8800298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50, 10, 2, 0.4 micrograms/g)
Number of subjects: 168
Study 8800298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 168
Study 8800298 — intervention group
Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 168
Study 1735081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks, modulated sinusoidally over 24 hours.
Number of subjects: 93
Study 1735081 — intervention group
Group type: COMPARATOR
Intervention: Infusion rate modulated according to circadian rhythms.
Number of subjects: 93
Study 1735081 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks.
Number of subjects: 93
Study 1735081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with good performance status (PS, 0 or 1, by WHO criteria).
Number of subjects: 93
Study 3883700 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment (10 ml of an antacid suspension seven times a day, buffering 367.5 mmol acid)
Number of subjects: 100
Study 3883700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3883700 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 100
Study 28699045 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard curriculum plus nutrition education for preschoolers (Group A)
Number of subjects: 164
Study 28699045 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard curriculum plus nutrition education for preschoolers and their caregivers (Group B)
Number of subjects: 164
Study 28699045 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum (Control Group)
Number of subjects: 164
Study 28739263 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine (0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg)
Number of subjects: 16
Study 28739263 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active control)
Number of subjects: 16
Study 28739263 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated treatments of subcutaneous ketamine
Number of subjects: 16
Study 25059750 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-avoidance task
Number of subjects: 284
Study 25059750 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-avoidance task + anti-smoking PSA
Number of subjects: 284
Study 25059750 — intervention group
Group type: COMPARATOR
Intervention: Control version of approach-avoidance task + control PSA
Number of subjects: 284
Study 24192334 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 24192334 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 21406307 — intervention group
Group type: EXPERIMENTAL
Intervention: LoBAG(30) diet (30% carbohydrate, 30% protein, 40% fat)
Number of subjects: 8
Study 21406307 — intervention group
Group type: COMPARATOR
Intervention: Control diet (15% protein, 55% carbohydrate, 30% fat)
Number of subjects: 8
Study 21406307 — intervention group
Group type: EXPERIMENTAL
Intervention: LoBAG(30) diet
Number of subjects: 8
Study 18424324 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer measurement and MSCT (DD‐CT strategy, n=903)
Number of subjects: 1819
Study 18424324 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer measurement, venous compression ultrasonography of the leg, and MSCT (DD‐US‐CT strategy, n=916)
Number of subjects: 1819
Study 18424324 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer measurement, venous compression ultrasonography of the leg, and MSCT (DD‐US‐CT strategy)
Number of subjects: 1819
Study 18424324 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐dimer measurement and MSCT (DD‐CT strategy)
Number of subjects: 1819
Study 16866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 microg every 3 h (group 1, n = 100)
Number of subjects: 200
Study 16866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol followed by oxytocin (group 2, n = 100)
Number of subjects: 200
Study 16866794 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (group 1)
Number of subjects: 200
Study 16866794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (group 1 and group 2)
Number of subjects: 200
Study 14678208 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg nickel sulfate hexahydrate
Number of subjects: 60
Study 14678208 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nickel sulfate hexahydrate
Number of subjects: 60
Study 14678208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg nickel sulfate hexahydrate
Number of subjects: 60
Study 14678208 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 60
Study 10520053 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen allergoid immunotherapy (IT) plus symptomatic treatment
Number of subjects: 37
Study 10520053 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 37
Study 7728484 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning
Number of subjects: 74
Study 7728484 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 74
Study 1822906 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel 50 mg/kg/day for 15 days
Number of subjects: 100
Study 1822906 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg/day for 30 days
Number of subjects: 100
Study 1822906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both albendazole and praziquantel
Number of subjects: 100
Study 6456140 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin base 2%
Number of subjects: 69
Study 6456140 — intervention group
Group type: COMPARATOR
Intervention: Vehicle/N alone
Number of subjects: 69
Study 31116355 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 31116355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study 26971543 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (ET)
Number of subjects: 98
Study 25014619 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) procedures
Number of subjects: 48
Study 25014619 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (PedsQL) and anxiety and depression scale (RCADS)
Number of subjects: 48
Study 23519054 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal mucoadhesive tablets
Number of subjects: 40
Study 23519054 — intervention group
Group type: COMPARATOR
Intervention: Placebo mucoadhesive tablets
Number of subjects: 40
Study 23519054 — intervention group
Group type: COMPARATOR
Intervention: Commercial mouthwash
Number of subjects: 40
Study 21184622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 800 mg
Number of subjects: 24
Study 21184622 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg alone (placebo control)
Number of subjects: 24
Study 18808378 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betulin-based oleogel twice daily
Number of subjects: 45
Study 18808378 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 45
Study 18808378 — intervention group
Group type: COMPARATOR
Intervention: Combination of cryotherapy with topical betulin-based oleogel
Number of subjects: 45
Study 17388922 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11
Study 17388922 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 11
Study 17388922 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 11
Study 17388922 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 11
Study 17388922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15002062 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 22
Study 15002062 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 22
Study 15002062 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (preoperative)
Number of subjects: 22
Study 15002062 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (postoperative)
Number of subjects: 22
Study 11255327 — intervention group
Group type: EXPERIMENTAL
Intervention: Total skin examination performed by a dermatologist on all children.
Number of subjects: 1116
Study 9702934 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg titrated to losartan 50 mg/hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 20
Study 9702934 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg titrated to 10 mg
Number of subjects: 20
Study 9247979 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 18
Study 9247979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1742817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms, n = 9)
Number of subjects: 19
Study 1742817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 19
Study 1742817 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms)
Number of subjects: 19
Study 1742817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6755789 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized saphenous vein grafts
Number of subjects: 446
Study 6755789 — intervention group
Group type: COMPARATOR
Intervention: Randomized or obligatory PTFE grafts
Number of subjects: 446
Study 6755789 — intervention group
Group type: COMPARATOR
Intervention: Obligatory PTFE grafts
Number of subjects: 446
Study 30650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients' platelets after weight loss
Number of subjects: 40
Study 30650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients' platelets before weight loss
Number of subjects: 40
Study 30650444 — intervention group
Group type: COMPARATOR
Intervention: Control group platelets with SERCA3 inhibition
Number of subjects: 40
Study 30650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ADP to agonist in obese patients and SERCA3-inhibited control platelets
Number of subjects: 40
Study 30650444 — intervention group
Group type: EXPERIMENTAL
Intervention: SERCA3 expression in obese patients' platelets
Number of subjects: 40
Study 30650444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-induced αIIbβ3 activation in obese patients' platelets
Number of subjects: 40
Study 27990692 — intervention group
Group type: EXPERIMENTAL
Intervention: CXP (creos xenoprotect)
Number of subjects: 49
Study 27990692 — intervention group
Group type: COMPARATOR
Intervention: BG (reference membrane)
Number of subjects: 49
Study 27990692 — intervention group
Group type: EXPERIMENTAL
Intervention: CXP
Number of subjects: 49
Study 27990692 — intervention group
Group type: COMPARATOR
Intervention: BG
Number of subjects: 49
Study 25388143 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help training program
Number of subjects: 34
Study 25388143 — intervention group
Group type: COMPARATOR
Intervention: Active control group (general cognitive stimulation activities)
Number of subjects: 34
Study 24278467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Rest (BR)
Number of subjects: 28
Study 24278467 — intervention group
Group type: COMPARATOR
Intervention: Sitting Control (SC)
Number of subjects: 28
Study 21073363 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (up to 50 mg daily)
Number of subjects: 2737
Study 21073363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study 18341017 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM (rifampicin, ofloxacin, and minocycline) administered by body weight to adults above 15 years; RMP (rifampicin) administered by body weight to children below 15 years.
Number of subjects: 300
Study 18341017 — intervention group
Group type: COMPARATOR
Intervention: Vitamins administered to non-treated group.
Number of subjects: 300
Study 16818928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysticidal drug therapy
Number of subjects: 942
Study 14505199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmeatal cochlear laser treatment (TCL) using diode lasers (lambda=635 nm, 7.8 mW cw, n=17 and lambda=830 nm, 20 mW cw, n=18) with a space irradiation of 4 J/cm2 at the site of maximal cochlear injury.
Number of subjects: 35
Study 14505199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmeatal cochlear laser treatment (TCL)
Number of subjects: 35
Study 11121366 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea chew candies containing green tea extracts (n = 22: 11 males, 11 females)
Number of subjects: 47
Study 11121366 — intervention group
Group type: COMPARATOR
Intervention: Placebo chew candies without active substances (n = 25: 12 males, 13 females)
Number of subjects: 47
Study 8896853 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 MAC sevoflurane/N2O anaesthesia (n = 10)
Number of subjects: 21
Study 8896853 — intervention group
Group type: COMPARATOR
Intervention: Equi‐MAC isoflurane/N2O anaesthesia (n = 11)
Number of subjects: 21
Study 1810328 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional composite core build‐up paste
Number of subjects: 30
Study 1810328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated core build‐up paste
Number of subjects: 30
Study 1810328 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass cermet
Number of subjects: 30
Study 1810328 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated product (Group 1)
Number of subjects: 30
Study 1810328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated products (Group 2 and Group 3)
Number of subjects: 30
Study 6864076 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy for 2 weeks
Number of subjects: 15
Study 6864076 — intervention group
Group type: COMPARATOR
Intervention: Control (normal iron status)
Number of subjects: 15
Study 31958790 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 16
Study 31958790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30759778 — intervention group
Group type: EXPERIMENTAL
Intervention: Chen-Style Tai Chi (TC)
Number of subjects: 43
Study 30759778 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization training (CST)
Number of subjects: 43
Study 30759778 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained unaltered lifestyle)
Number of subjects: 43
Study 28333860 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 353
Study 28333860 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 353
Study 26915276 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction group
Number of subjects: 45
Study 26915276 — intervention group
Group type: COMPARATOR
Intervention: In situ fusion group
Number of subjects: 45
Study 25085447 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive wellbeing intervention
Number of subjects: 57
Study 25085447 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the IHDP intervention
Number of subjects: 229
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's report on the youth's school progress
Number of subjects: 229
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth report of behavioral problems
Number of subjects: 229
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth's expectations of future success
Number of subjects: 229
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth's relationship with their parents
Number of subjects: 229
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed IQ
Number of subjects: 229
Study 22664795 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of the youth's educational attainment
Number of subjects: 229
Study 19348544 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated distributions of pronunciation times using combinations of lognormal and power-law behavior.
Number of subjects: 1100
Study 19348544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard function simulations.
Number of subjects: 1100
Study 17585028 — intervention group
Group type: COMPARATOR
Intervention: Control diet (93 microg phylloquinone/d) for 5 days
Number of subjects: 9
Study 17585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone-restricted diet (11 microg/d) for 15 days
Number of subjects: 9
Study 17585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Repletion diet with phylloquinone (206 microg/d) for 10 days
Number of subjects: 9
Study 17585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Repletion diet with dihydrophylloquinone (240 microg/d) for 10 days
Number of subjects: 9
Study 17585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Repletion diet with either phylloquinone or dihydrophylloquinone
Number of subjects: 9
Study 17585028 — intervention group
Group type: EXPERIMENTAL
Intervention: Total urinary excretion
Number of subjects: 9
Study 15378434 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) prophylaxis
Number of subjects: 158
Study 15378434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 12214463 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP therapy (TXL 160 mg/m2 3 h, day 2, ADM 45 mg/m2, day 1, CDDP 50 mg/m2 day 1)
Number of subjects: 0
Study 12214463 — intervention group
Group type: COMPARATOR
Intervention: AP therapy (ADM 60 mg/m2, CDDP 50 mg/m2)
Number of subjects: 0
Study 12078199 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 tablets of albendazole composite
Number of subjects: 5590
Study 12078199 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 tablets of albendazole composite
Number of subjects: 5590
Study 12078199 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 400 mg of albendazole
Number of subjects: 5590
Study 12078199 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 10 mg base/kg of pyrantel pamoate
Number of subjects: 5590
Study 12078199 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 tablets of albendazole composite
Number of subjects: 5590
Study 12078199 — intervention group
Group type: COMPARATOR
Intervention: Single dose of pyrantel pamoate
Number of subjects: 5590
Study 7804990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunny Days, Healthy Ways curriculum (elementary school)
Number of subjects: 0
Study 7804990 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Sun Safe curriculum (preschool)
Number of subjects: 0
Study 2686955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g) administered as i.v. bolus 30 min before operation
Number of subjects: 686
Study 2686955 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (2 g) administered as i.v. bolus 30 min before operation
Number of subjects: 686
Study 4597119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% salbutamol
Number of subjects: 15
Study 4597119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% rimiterol
Number of subjects: 15
Study 4597119 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 15
Study 31466530 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely Randomized Tree (ERT) algorithm
Number of subjects: 0
Study 31466530 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT approach
Number of subjects: 0
Study 31466530 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT methodology
Number of subjects: 0